Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Authors

  • Lieneke F.M. Ariëns National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, NL-3584 CX Utrecht, The Netherlands
  • Daphne S. Bakker
  • Lotte S. Spekhorst
  • Jorien van der Schaft
  • Judith L. Thijs
  • Inge Haeck
  • Annebeth E. Flinterman
  • Marijke Kamsteeg
  • Marie L.A. Schuttelaar
  • Marjolein S. De Bruin-Weller

DOI:

https://doi.org/10.2340/00015555-3886

Keywords:

atopic dermatitis, dupilumab, health-economics, absenteeism, presenteeism

Abstract

Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7–780.8)) to week 52 (€0.0 (0.0–211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice.

Downloads

Download data is not yet available.

References

Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.

https://doi.org/10.1016/S0140-6736(15)00149-X

Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol 2017; 137: 26-30.

https://doi.org/10.1016/j.jid.2016.07.012

Ariens LFM, van Nimwegen KJM, Shams M, de Bruin DT, van der Schaft J, van Os-Medendorp H, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol 2019; 99: 762-768.

https://doi.org/10.2340/00015555-3212

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 2018; 78: 54-61.

https://doi.org/10.1016/j.jaad.2017.08.002

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol 2017; 77: 274-279.

https://doi.org/10.1016/j.jaad.2017.04.019

Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immun 2017; 140: 633-643.

https://doi.org/10.1016/j.jaci.2017.07.006

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.

https://doi.org/10.1016/S0140-6736(17)31191-1

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.

https://doi.org/10.1056/NEJMoa1610020

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, et al. Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178: 1083-1101.

https://doi.org/10.1111/bjd.16156

Ariens LF, van der Schaft J, Bakker DS, Balak D, Romeijn ML, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy 2020; 75: 116-126.

https://doi.org/10.1111/all.14080

de Wijs LEM, Bosma AL, Erler NS, Hollestein LM, Gerbens LAA, Middelkamp-Hup MA, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol 2020; 182: 418-426.

https://doi.org/10.1111/bjd.18179

Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-151.

https://doi.org/10.1016/j.jaad.2019.02.053

Bosma AL, de Wijs LEM, Hof MH, van Nieuwenhuizen BR, Gerbens LAA, Middelkamp-Hup MA, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol 2020; 83: 1375-1384.

https://doi.org/10.1016/j.jaad.2020.05.128

Ariens LF, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-1009.

https://doi.org/10.1016/j.jaad.2020.08.127

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.

https://doi.org/10.2165/00019053-199304050-00006

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.

https://doi.org/10.1034/j.1600-0625.2001.100102.x

Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.

https://doi.org/10.1111/bjd.12590

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769.

https://doi.org/10.1111/bjd.17744

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.

https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

Zorginstituut N. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016. Available from: https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg (English version is available from: https://english.zorginstituutnederland.nl/publications/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare).

de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, et al. Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. J Am Acad Dermatol 2020; 83: 1499-1501.

https://doi.org/10.1016/j.jaad.2020.05.142

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475-2485.

https://doi.org/10.1056/NEJMoa1804093

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486-2496.

https://doi.org/10.1056/NEJMoa1804092

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 2018; 35: 737-748.

https://doi.org/10.1007/s12325-018-0702-4

Published

2021-10-19

How to Cite

Ariëns, L. F., Bakker, D. S., Spekhorst, L. S., van der Schaft, J., Thijs, J. L., Haeck, I., … De Bruin-Weller, M. S. (2021). Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry. Acta Dermato-Venereologica, 101(10), adv00573. https://doi.org/10.2340/00015555-3886